Use of t-cell engaging proteins in the treatment of cancer

Abstract

The present invention relates to T-cell engaging protein comprising a first antigen binding unit specifically binding to DLL3 and a second antigen binding unit specifically binding to CD3 for use in a method for treating a DLL3-positive cancer or a cancer selected from a Neuroendocrine Neo-plasm (NEN), Merkel cell carcinoma (MCC), medullary thyroidal carcinoma and glioma in a subject exhibiting at least a threshold of DLL3-positivity, expressed in percents, the method comprising administering to the subject a dose of said T-cell engaging protein, wherein said T-cell engaging protein comprises a first antigen binding unit specifically binding to DLL3, comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:13 (CDR1), SEQ ID NO:14 (CDR2) and SEQ ID NO:15 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:16 (CDR1), SEQ ID NO:17 (CDR2) and SEQ ID NO:18 (CDR3) and a second antigen binding unit specifically binding to CD3 comprising light chain CDRs comprising the amino acid sequences of SEQ ID NO:55 (CDR1), SEQ ID NO:56 (CDR2) and SEQ ID NO:57 (CDR3) and heavy chain CDRs comprising the amino acid sequences of SEQ ID NO:58 (CDR1), SEQ ID NO:59 (CDR2) and SEQ ID NO:60 (CDR3).

Images